For World Heart Day 2025, observed annually on Sept. 29 to raise public awareness of cardiovascular diseases and their prevention, Healthcare IT News has been tracking new technologies – and new ...

BOSTON--(BUSINESS WIRE)--Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis software to help physicians diagnose ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that its Plaque-IQ ...

WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone 1, were ...

In the original HOPE trial, a total of 9541 patients aged ≥ 55 years at high risk for cardiovascular events, but who did not have left ventricular dysfunction or heart failure, were randomized in a ...

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and ...

This systematic literature review and pooled rates analysis investigated the standard of care for patients with heart failure in the US post hospital discharge. Results: There were 31 studies that met ...

Endothelial dysfunction is a hallmark of cardiovascular disease (CVD) and plays a central role in vascular inflammation, ...